Geneva, Switzerland

Robert Johannes Lutjens

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 79(Granted Patents)


Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Robert Johannes Lutjens: A Pioneer in Pharmacological Innovations

Introduction:

Robert Johannes Lutjens is a distinguished inventor based in Geneva, Switzerland, renowned for his groundbreaking work in the field of pharmacology. With a portfolio of 8 patents to his name, he has significantly contributed to the advancements in neurological and psychiatric disorder treatments.

Latest Patents:

Lutjens' latest patent pertains to the development of 1, 4-disubstituted 3-cyano-pyridone derivatives as positive allosteric modulators of MGLUR2-receptors. These compounds play a pivotal role in the treatment and prevention of various central nervous system disorders, including anxiety, schizophrenia, migraine, depression, and epilepsy.

Career Highlights:

Having worked with esteemed companies such as Janssen Pharmaceuticals, Inc. and Addex Pharma S.A., Lutjens has honed his expertise in drug discovery and development. His innovative approach has led to the creation of novel pharmacological compounds that have the potential to revolutionize the treatment landscape for neurological and psychiatric disorders.

Collaborations:

Throughout his career, Lutjens has collaborated closely with industry peers, including Jose Maria Cid-Nunez and Andres Avelino Trabanco-Suarez. Together, they have shared insights, expertise, and ideas to drive innovation and bring novel pharmaceutical solutions to fruition.

Conclusion:

In conclusion, Robert Johannes Lutjens stands as a beacon of innovation in the field of pharmacology, inspiring future generations of inventors to push the boundaries of what is possible in drug development. His contributions to the medical field are invaluable, and his patents serve as a testament to his unwavering dedication to improving the quality of life for individuals affected by neurological and psychiatric disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…